Filing Details

Accession Number:
0001415889-24-009989
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-03 16:15:13
Reporting Period:
2024-04-01
Accepted Time:
2024-04-03 16:15:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1671927 Immunocore Holdings Plc IMCR Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1969525 Amber Tina Leger St C/O Immunocore Holdings Plc
92 Park Drive, Milton Park, Abingdon
Oxfordshire X0 OX14 4RY
Chief Hr Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2024-04-01 4,375 $29.87 4,375 No 4 M Direct
Ordinary Shares Disposition 2024-04-01 4,375 $64.06 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Employee Share Option (Right to Buy) Disposition 2024-04-01 4,375 $0.00 4,375 $29.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,000 2032-03-31 No 4 M Direct
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.73 to $64.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. 25% of the shares subject to the option award vested on April 1, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.